Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13G

bioAffinity Technologies, Inc.

BIAFNASDAQEQUITYCurrent

Beneficial Ownership Report

Filed Nov 19, 2026Accepted Nov 19, 2026, 4:38 PM ESTFiling CIK 1712762Accession 0001475597-26-000255
Share

Structured filing — SCHEDULE 13G

primary_doc.xml

Open full document ↗

Subject company

Company
bioAffinity Technologies, Inc.
Company CIK
0001712762
Street
3300 NACOGDOCHES ROAD
Street (continued)
SUITE 216
City
SAN ANTONIO
State / country code
TX
Postal code
78217

Statement details

Security class
Common Stock
Event date
09/30/2026
Rule designation
Rule 13d-1(b)

Reporting person 1

Name
HRT FINANCIAL LP
Citizenship / organization
DE
Reporting person type
BD
Aggregate amount owned
127,132.00
Percent of class
10.9
Sole voting power
127,132.00
Shared voting power
0.00
Sole dispositive power
127,132.00
Shared dispositive power
0.00
Comments
The percentage reported herein is based on 1,166,625 shares of Common Stock outstanding as of September 30, 2026, as reported by bioAffinity Technologies, Inc. in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the Securities and Exchange Commission on November 6, 2026, plus 986 shares of Common Stock issuable upon the exercise of certain warrants held by HRT Financial LP, for a denominator of 1,167,611 shares.

Item 1

Issuer

bioAffinity Technologies, Inc.

Principal executive office address

3300 NACOGDOCHES ROAD, SUITE 216, SAN ANTONIO, TEXAS, 78217.

Item 2

Citizenship

Delaware

Filing person

HRT Financial LP, a Delaware limited partnership

Principal business or residence address

c/o Hudson River Trading LLC, 3 World Trade Center, 175 Greenwich Street, 76th Floor, New York, NY 10007

Item 3

Not applicable indication

N

Type of filing person

BD

Item 4

Percent of class

The response to Row 11 of the cover page is incorporated herein by reference and sets forth the information required by this item.

Amount beneficially owned

The ownership information reported herein is as of September 30, 2026. The reported aggregate amount includes 126,146 shares of Common Stock held directly and 986 shares of Common Stock issuable upon the exercise of certain warrants held by the Reporting Person. The response to Row 9 of the cover page is incorporated herein by reference and sets forth the information required by this item.

Sole voting power

The response to Row 5 of the cover page is incorporated herein by reference and sets forth the information required by this item.

Shared voting power

The response to Row 6 of the cover page is incorporated herein by reference and sets forth the information required by this item.

Sole dispositive power

The response to Row 7 of the cover page is incorporated herein by reference and sets forth the information required by this item.

Shared dispositive power

The response to Row 8 of the cover page is incorporated herein by reference and sets forth the information required by this item.

Item 5

Not applicable indication

Y

Ownership of 5% or less

N

Item 6

Not applicable indication

Y

Item 7

Not applicable indication

Y

Item 8

Not applicable indication

Y

Item 9

Not applicable indication

Y

Item 10

Not applicable indication

N

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Signature 1

Reporting person
HRT FINANCIAL LP
Signed
Adam Nunes
Title
CEO
Date
11/19/2026

Company context

bioAffinity Technologies, Inc. addresses the need for non-invasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath ® Lung, is a non-invasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.

Current securities

Recent company filings

  1. 4 filingNov 19, 2026
  2. 3 filingNov 19, 2026
  3. Other EventsNov 19, 2026
  4. Other EventsNov 17, 2026
  5. Results of Operations and Financial ConditionNov 6, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.